Pharmacokinetics of long-acting cefovecin in copper rockfish (Sebastes caurinus)

Kathryn E. Seeley Point Defiance Zoo & Aquarium, 5400 N Pearl St, Tacoma, WA 98407.

Search for other papers by Kathryn E. Seeley in
Current site
Google Scholar
PubMed
Close
 DVM
,
Karen N. Wolf Point Defiance Zoo & Aquarium, 5400 N Pearl St, Tacoma, WA 98407.

Search for other papers by Karen N. Wolf in
Current site
Google Scholar
PubMed
Close
 MS, DVM
,
Melissa A. Bishop Point Defiance Zoo & Aquarium, 5400 N Pearl St, Tacoma, WA 98407.

Search for other papers by Melissa A. Bishop in
Current site
Google Scholar
PubMed
Close
,
Megan Turnquist College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331.

Search for other papers by Megan Turnquist in
Current site
Google Scholar
PubMed
Close
 BS
, and
Butch KuKanich Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506.

Search for other papers by Butch KuKanich in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE To assess the pharmacokinetic properties of cefovecin in a cold-water teleost species.

ANIMALS 10 healthy adult copper rockfish (Sebastes caurinus), sex unknown.

PROCEDURES Cefovecin (16 mg/kg) was administered SC to the rockfish. Blood samples were collected at predetermined points for measurement of plasma cefovecin concentrations (3 samples/fish). Plasma cefovecin concentrations were measured via liquid chromatography with mass spectrometry. Pharmacokinetic analysis was performed by means of naïve pooled analysis and compartmental modeling. Plasma protein binding of cefovecin was determined by ultrafiltration.

RESULTS Cefovecin administration appeared to be well tolerated by the rockfish. Pharmacokinetic analysis resulted in a maximum plasma concentration of 104.8 μg/mL at 2.07 hours after administration. Plasma terminal half-life was 32.5 hours, and area under the curve was 5,132 h·g/mL. Plasma protein binding was low (< 10%) for plasma concentrations of 10 and 100 μg of cefovecin/mL when assessed at 7.8° and 20°C. Plasma concentrations > 1 μg/mL persisted for the full 7-day follow-up period.

CONCLUSIONS AND CLINICAL RELEVANCE SC administration of cefovecin to copper rockfish at a dose of 16 mg/kg yielded plasma concentrations > 1 μg/mL that persisted to 7 days, but some interindividual variability was observed. The low degree of plasma protein binding but high circulating concentration of free drug may allow an extended administration interval in rockfish. Studies are needed to assess the efficacy and safety of this dose in rockfish.

Abstract

OBJECTIVE To assess the pharmacokinetic properties of cefovecin in a cold-water teleost species.

ANIMALS 10 healthy adult copper rockfish (Sebastes caurinus), sex unknown.

PROCEDURES Cefovecin (16 mg/kg) was administered SC to the rockfish. Blood samples were collected at predetermined points for measurement of plasma cefovecin concentrations (3 samples/fish). Plasma cefovecin concentrations were measured via liquid chromatography with mass spectrometry. Pharmacokinetic analysis was performed by means of naïve pooled analysis and compartmental modeling. Plasma protein binding of cefovecin was determined by ultrafiltration.

RESULTS Cefovecin administration appeared to be well tolerated by the rockfish. Pharmacokinetic analysis resulted in a maximum plasma concentration of 104.8 μg/mL at 2.07 hours after administration. Plasma terminal half-life was 32.5 hours, and area under the curve was 5,132 h·g/mL. Plasma protein binding was low (< 10%) for plasma concentrations of 10 and 100 μg of cefovecin/mL when assessed at 7.8° and 20°C. Plasma concentrations > 1 μg/mL persisted for the full 7-day follow-up period.

CONCLUSIONS AND CLINICAL RELEVANCE SC administration of cefovecin to copper rockfish at a dose of 16 mg/kg yielded plasma concentrations > 1 μg/mL that persisted to 7 days, but some interindividual variability was observed. The low degree of plasma protein binding but high circulating concentration of free drug may allow an extended administration interval in rockfish. Studies are needed to assess the efficacy and safety of this dose in rockfish.

All Time Past Year Past 30 Days
Abstract Views 59 0 0
Full Text Views 1105 806 20
PDF Downloads 188 73 9
Advertisement